Evidence map›Paper›PMID 26957112›Full record

ReviewJournal of hematology & oncology2016

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.

Jingjing Wu, Mingzhi Zhang, Delong Liu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of hematology & oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 2 pooled it
17.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 2 syntheses or guidelines pooled it, 246 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Kinase Inhibitors for Targeted Cancer Therapy.Current topics in medicinal chemistry · 2026
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jingjing WuDepartment of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Mingzhi ZhangDepartment of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Delong LiuDepartment of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Delong_liu@nymc.edu.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.

Indexed as

Agammaglobulinaemia Tyrosine KinaseAnimalsBenzamidesClinical Trials as TopicHematologic NeoplasmsHumansProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazinesTreatment OutcomeXenograft Model Antitumor AssaysacalabrutinibAgammaglobulinaemia Tyrosine KinaseBenzamidesBTK protein, humanProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazines

Identifiers

PMID26957112
PMCPMC4784459
OpenAlexW2296618733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.